Aura Biosciences Stock Forecast
NASDAQ: AURAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 8, 12:02 PM ET
AURA analyst consensus
Consensus (6 analysts)
none
Avg. price target
$16.60+156.97%
- Strong buy 1
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 6 Wall Street analysts covering Aura Biosciences (2026-10-08), 6 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $16.60, with a high estimate of $23.00 and a low estimate of $12.00. The average target implies upside of 157.0% from the current price of $6.46.
The spread between the highest and lowest targets is 91.7%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for AURA.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 17% |
| Buy | 5 | 83% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $12.00 | +85.76% |
| Average target | $16.60 | +156.97% |
| High target | $23.00 | +256.04% |